Budesonide Cir Capsules (Once Or Twice Daily Divided-Dose) in Active Crohn's Disease: A Randomized Placebo-Controlled Study in The United States

Tremaine, William J.; Hanauer, Stephen B.; Katz, Seymour; Winston, Barry; Levine, Jeffrey G.; Persson, Tore; Persson, Anders

doi:10.1111/j.1572-0241.2002.05835.x

Cited by 107 publications

(34 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two randomized, double-blind, placebo-controlled studies investigated the treatment of flare in patients with mild-to-moderate active Crohn's disease of the ileum or ascending colon, and showed that controlled-ileal-release budesonide capsules were more effective than placebo for induction of remission (Table 1) [Greenberg et al 1994;Tremaine et al 2002]. A controlled-ileal-release formulation of budesonide more effectively induced remission than a slow-release formulation of mesalamine in patients with active Crohn's disease [Thomsen et al 1998].…”

Section: Efficacy In Crohn's Diseasementioning

confidence: 99%

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Prantera

Marconi

2013

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are a group of inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract. Reported prevalence is high in the United States and northern Europe, while the incidence varies greatly across the rest of Europe. Glucocorticosteroids are the standard treatment for IBD, but due to adverse events their use can be limited. However, new formulations of glucocorticosteroids have been developed to reduce systemic activation. The aim of this review was to assess and summarize the efficacy and safety of new formulations of glucocorticosteroids. A MEDLINE search identified publications focused on new formulations of nonsystemic steroidbased drugs for IBD and benefits and limitations of each of the new glucocorticosteroid formulations were identified. Budesonide has good efficacy and is an established treatment for Crohn's disease; it has been shown to be beneficial for the induction of remission in these patients, although it is not recommended for the maintenance of induced remission. Glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD. However, a recent study suggested that beclomethasone dipropionate may be effective for prolonged treatment in patients in the postacute phase of Crohn's disease who were treated with a short course of systemic steroids. The efficacy of fluticasone propionate and prednisolone metasulphobenzoate in IBD is not well established given the small number of patients enrolled in the few published clinical trials. While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted.

show abstract

Section: Efficacy In Crohn's Diseasementioning

confidence: 99%

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Prantera

Marconi

2013

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Well controlled studies have revealed that budesonide is significantly more effective than placebo and 5-ASA, and is about as effective as conventional corticosteroids for inducing remission in active CD. [92][93][94] Therefore, budesonide has been recommended as a first-line therapy for mild to moderate CD of the ileum and proximal colon in an American Gastroenterological Association position statement and in the European Crohn's and Colitis Organization Consensus. 95,96 For those patients who do not respond to the first-line therapy described above and for those with moderate to severe CD, oral prednisone 40-60 mg/day should be given.…”

Section: Medical Management 1) Induction Of Remissionmentioning

confidence: 99%

Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics

Kim¹

2010

Gut Liver

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) describes chronic inflammatory disease of the intestines and has a variable course; Crohn's disease and ulcerative colitis comprise the two main forms of the condition. Although IBD occurs worldwide, its epidemiologic and clinical characteristics vary depending upon the geographic location and the ethnicity of the population. Identifying the characteristic features of IBD in populations living in different geographical locations and with different ethnicities may provide significant clues about its etiology and pathophysiology, which in turn may be helpful in the development of more appropriate treatment strategies for IBD for these different populations. Therefore, it is important for each country and region to evaluate critically the epidemiology, genomics, and clinical characteristics of IBD among its own population. We have performed a critical review of the recent data in Korea, and describe herein the current epidemiologic and genotypic status, as well as the clinical manifestations and therapeutic responses of IBD that are unique to Korean patients. (Gut Liver 2010;4:1-14)

show abstract

“…[4][5][6][7][8][9][10][11][12] Validity (comparison of a new index against a reference measure), reliability (test of consistency of the index when readministered under similar conditions at two separate intervals), and responsiveness (ability of the index to measure clinically important change over time) of the short CDAI were also evaluated in these nine studies. 13 The protocols for the nine studies were approved by the Institutional Review Boards at each of the participating centers and all patients gave written informed consent.…”

Section: Included Patients and Trialsmentioning

confidence: 99%

Short CDAI: Development and validation of a shortened and simplified Crohnʼs disease activity index

Thia

Faubion

Loftus

et al. 2011

Inflammatory Bowel Diseases

Self Cite

109

View full text Add to dashboard Cite

show abstract

Budesonide Cir Capsules (Once Or Twice Daily Divided-Dose) in Active Crohn's Disease: A Randomized Placebo-Controlled Study in The United States

Cited by 107 publications

References 12 publications

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity

Inflammatory Bowel Disease in Korea: Epidemiological, Genomic, Clinical, and Therapeutic Characteristics

Short CDAI: Development and validation of a shortened and simplified Crohnʼs disease activity index

Contact Info

Product

Resources

About